FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/04/066053 [Registered on: 22/04/2024] Trial Registered Prospectively
Last Modified On: 22/04/2024
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug 
Study Design  Other 
Public Title of Study   IMPACT OF INTERVENTION WITH FRUSEMIDE(LASIX)/DIALYSIS COMPARED WITH STANDARD INTERVENTION IN CRITICALLY ILL/ICU PATIENTS ON DEATH IN A TERTIARY CARE HOSPITAL 
Scientific Title of Study   IMPACT OF PROTOCOLIZED DE-RESUSCITATION WITH FRUSEMIDE/RENAL REPLACEMENT THERAPY COMPARED WITH STANDARD INTERVENTION IN CRITICALLY ILL PATIENTS ON MORTALITY IN A TERTIARY CARE HOSPITAL 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  AMRITA SHAH 
Designation  DrNB Trainee 
Affiliation  Manipal hospitals yeshwanthpur 
Address  CRITICAL CARE MEDICINE ICU 1 ST FLOOR Manipal Hospitals Yeshwanthpur, Brigade Gateway 26, 4, 1st Main Rd, beside Metro, Malleshwaram, Bengaluru,

Bangalore
KARNATAKA
560055
India 
Phone  9864872622  
Fax    
Email  shahamrita8@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  DR PRADEEP RANGAPPA 
Designation  CONSULTANT/GUIDE 
Affiliation  Manipal hospitals yeshwanthpur 
Address  Manipal Hospitals Yeshwanthpur, Brigade Gateway 26, 4, 1st Main Rd, beside Metro, Malleshwaram, Bengaluru,

Bangalore
KARNATAKA
560055
India 
Phone  9864872622  
Fax    
Email  prangap939@gmail.com  
 
Details of Contact Person
Public Query
 
Name  AMRITA SHAH 
Designation  DrNB Trainee 
Affiliation  Manipal hospitals yeshwanthpur 
Address  CRITICAL CARE MEDICINE ICU 1 ST FLOOR Manipal Hospitals Yeshwanthpur, Brigade Gateway 26, 4, 1st Main Rd, beside Metro, Malleshwaram, Bengaluru,

Bangalore
KARNATAKA
560055
India 
Phone  9864872622  
Fax    
Email  shahamrita8@gmail.com  
 
Source of Monetary or Material Support  
CRITICAL CARE MEDICINE ICU 1ST FLOOR MANIPAL HOSPITAL YESHWANTHPUR, Inside Brigade gateway, Malleshwaram, 560066 
 
Primary Sponsor  
Name  AMRITA SHAH 
Address  MANIPAL HOSPITALS YESHWANTHPUR,  
Type of Sponsor  Private hospital/clinic 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
AMRITA SHAH  MANIPAL HOSPITALS YESHWANTHPUR  Brigade Gateway 26, 4, 1st Main Rd, beside Metro, Malleshwaram, Bengaluru, Karnataka 560055
Bangalore
KARNATAKA 
9864872622

shahamrita8@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee Columbia Asia Hospitals  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: R098||Other specified symptoms and signsinvolving the circulatory and respiratory systems,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  FRUSEMIDE/RENAL REPLACEMENT THERAPY STANDARD THERAPY  Frusemide (Injection Lasix 20 mg) 0.5 mg/kg bolus f/b infusion 2.5 mg/hour  titrated to achieve negative balance 1L /day after D3 for 2 days. If target not achieved, can be increased upto 20 mg/hour (RADAR-2 trial). Diuretics not considered if patient on Renal replacement therapy. If no evidence of fluid overload/negative balance achieved after day 3-day 5 target neutral balance If presence of fluid overload between day 3/day of stabilization-day 5/48 hours post stabilization, then active de-resuscitation followed. Intervention: Aimed at targeting negative or neutral balance depending on net balance after D3/day of stabilization -D5/48 hours after stabilization in the 1st week.  
Comparator Agent  STANDARD THERAPY   TARGETING A NEGATIVE BALANCE FROM D3/DAY OF STABILIZATION 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  99.00 Year(s)
Gender  Both 
Details  At least 2 days of ICU admission
Older than 18 years
 
 
ExclusionCriteria 
Details  1. Patient’s refusal.
2. Patient younger than 18 years.
3. Length of ICU stay < 2 days
4. Lactates>4
5. Norepinephrine/epinephrine> 0.2 mcg/kg/min/>1 vasopressor in use
6. Patients with subarachnoid haemorrhage
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Participant Blinded 
Primary Outcome  
Outcome  TimePoints 
Mortality at 28 days  28 DAYS 
 
Secondary Outcome  
Outcome  TimePoints 
Hospital and ICU mortality
Mechanical ventilator free days
ICU length of stay (ICU-LOS)
New adverse effects – hypernatremia, metabolic alkalosis, new AKI
Change in SOFA Score
 
28 DAY 
 
Target Sample Size   Total Sample Size="198"
Sample Size from India="198" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   05/05/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   not applicable yet 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - YES
  1. What data in particular will be shared?
    Response - All of the individual participant data collected during the trial, after de-identification.

  2. What additional supporting information will be shared?
    Response -  Study Protocol
    Response -  Statistical Analysis Plan
    Response - Informed Consent Form
    Response - Clinical Study Report

  3. Who will be able to view these files?
    Response - Anyone

  4. For what types of analyses will this data be available?
    Response - Any purpose.

  5. By what mechanism will data be made available?
    Response (Others) - 

  6. For how long will this data be available start date provided 05-05-2024 and end date provided 11-05-2025?
    Response - Immediately following publication. No end date.

  7. Any URL or additional information regarding plan/policy for sharing IPD? 
    Additional Information - NIL
Brief Summary  

  Fluid administration in ICU has been divided 4 phases: Resuscitation, Optimisation, Stabilisation, and Evacuation (ROSE), followed by risk of Hypoperfusion. Intravenous fluid is administered during initial phase of resuscitation to counter dehydration, as diluents to give medications and in cases of shock.1 In certain cases, this can result in a positive fluid balance. During stabilization phase, we target for late Conservative Fluid Management (LCFM) and during evacuation phase goal directed fluid removal is advocated. Malbrain et al (2014) defined late Conservative Fluid Management (LCFM) as two consecutive days of negative fluid balance within the first week of ICU stay. Late Goal Directed Fluid Removal (LGFR) – defined as more aggressive and active fluid removal by means of diuretics and renal replacement therapy with net ultrafiltration.1

 

A positive cumulative fluid balance in critically ill patients have been associated with poor clinical outcomes including poly-compartment syndrome, increased mortality and intra-abdominal hypertension.1 In septic patients, a positive fluid balance was found to be a strongest predictors of death.2 The fluid overload state can result in affecting the cardiovascular system (causing myocardial oedema, conduction disturbance, impaired contractility, diastolic dysfunction, myocardial depression, pericardial effusion), central nervous system(cerebral oedema, impaired cognition, delirium , increased intracranial pressure, cerebral perfusion pressure  and intra-ocular pressure), respiratory system( causing pulmonary oedema, pleural effusion, altered pulmonary and chest wall elastance, impaired gas exchange and increased work of breathing), gastrointestinal system(impaired synthetic function, cholestasis, Impaired cytochrome P 450 activity, hepatic compartment syndrome), renal system(renal interstitial oedema, increased renal blood flow, increased renal vascular resistance ,salt retention , water retention and renal compartment syndrome), gastro-intestinal system(ascites formation, gut oedema ,malabsorption ,ileus , increased Abdominal perfusion pressure, increased  Bowel contractility , increased IAP and APP and abdominal compartment syndrome).1 A positive fluid balance is independently associated with impaired organ function and an increased risk of death.2,3

Following hemodynamic stabilization, it is important to understand whether liberal or conservative fluid management and strategic removal of excess fluid impacts ICU outcomes. The reason we have taken up this study is -even though most studies have mentioned a positive fluid balance is harmful after optimal stabilization1,2,3, studies on how much, methods of removal and to what extent the removal of excess fluids can help in such outcomes are varied and with variable results. We have designed a protocol for the same to assess its impact on clinical outcomes.

  1. Malbrain, Manu & Marik, Paul & Witters, Ine & Cordemans, Colin & Kirkpatrick, Andrew & Roberts, Derek & Regenmortel, Niels. Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: A systematic review with suggestions for clinical practice. Anaesthesiology intensive therapy.Nov 2014;46(5):361-80
  2. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D; Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006 Feb;34(2):344-53. 
  3. Murphy CV, Schramm GE, Doherty JA et al.: The importance of fluid management in acute lung injury secondary to septic shock. Chest 2009; 136: 102�’109.

 
Close